Braunstein, L. Z., Mitchell, M. P., Bandos, H., Sikov, W. M., Khan, A. J., Chen, P. Y., Ganz, P. A., Jagsi, R., White, J. R., Cecchini, R. S., Kang, H., Puhalla, S. L., Bolton, K. L., Connolly, E. P., Stringer-Reasor, E. M., Gergelis, K. R., Julian, T. B., Mamounas, E. P., & Wolmark, N. (2025). NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. Future Oncology, 1–9. https://doi.org/10.1080/14796694.2025.2511586